生物制剂在SAPHO综合征的治疗  

Application of Biologics to the Treatment of SAPHO Syndrome

作　　者：李忱[1] 刘晋河[1] 张文[2] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院中医科,北京100730 [2]中国医学科学院北京协和医学院北京协和医院风湿免疫科,北京100730

出　　处：《中华临床免疫和变态反应杂志》2016年第3期281-285,共5页Chinese Journal of Allergy & Clinical Immunology

摘　　要：SAPHO综合征是罕见病,具有显著炎性皮肤和骨关节表现。关于本病的治疗多参照血清阴性脊柱关节病,生物制剂近10年也有应用于本病的报道。肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)拮抗剂通常用于治疗对常规治疗无应答的患者,证明对骨关节有显著疗效。近期白细胞介素(interleukin,IL)-1单抗也证实治疗有效,目前认为Th17相关信号通路可能参与本病,乌司努单抗也有个案报道,IL-17单抗在银屑病关节炎取得良好效果,有望用于本病的治疗。SAPHO syndrome is a rare disease presented with dermatitis, osteitis and arthritis. The treatment for SAPHO syndrome traditionally follows that of seronegative spondyloarthropathy. Biological agents have been used as a new therapy for seronegative spondyoarthropathy in recent 10 years. Tumor necrosis factor-or （TNF-ot） blockers has been proposed to be effective in patients who are non-responders to standard treatment. Recently, Interleukin-1 （IL-1 ） blockers and Ustekinumab were also reported to be effective in SAPHO syndrome. On the other hand, since TH17 related pathway may be involved in the pathophysiological process of SAPHO syndrome, IL-17 blocker has been proposed to be a potential therapy, which has been tested to be effective in psoriatic arthritis, therefore, it may be a possible new therapy for SAPHO syndrome.

关 键 词：SAPHO综合征 生物制剂 治疗 

分 类 号：R597[医药卫生—内科学]